Added anti-viral improves response, halves duration of hepatitis C treatment

Apr 30, 2009

The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).

"Standard treatment for the most common type of hepatitis C is 48 weeks of a combination of two drugs, peginterferon alfa-2a and ribavirin, which cures less than half of patients and has significant side effects that make it very difficult for some patients to continue their treatment," said John McHutchison, M.D., a hepatologist and gastroenterologist and researcher at the DCRI, and lead investigator on this study. "Our study found that by combining the standard therapy with the direct anti-viral drug telaprevir, we could reduce the duration of treatment by 50 percent, to 24 weeks, and, at the same time, improve the cure rate by 50 percent."

The researchers published their findings in the April 30, 2009 issue of the New England Journal of Medicine. The study was funded by Vertex Pharmaceuticals, the maker of the drug telaprevir, a protease inhibitor that works by blocking an enzyme that the hepatitis C virus needs in order to replicate itself.

In a randomized, Phase IIb, double-blinded, 37-center study of telaprevir in combination with peginterferon alfa-2a and ribavirin, the researchers examined the responses of 250 patients on four trial arms.

The researchers measured rates of sustained viral response - or SVR - defined as 24 weeks during which the hepatitis C virus remains undetectable in the body after the completion of therapy.

"We observed that 67 percent of patients who received standard therapy for 48 weeks in conjunction with 12 weeks of telaprevir were cured of their hepatitis C," McHutchison said. "The rate was 61 percent in the group that took the standard therapy for only 24 weeks in combination with 12 weeks of telaprevir, suggesting that many patients may respond to treatment in only six months as compared to about eleven months, which is significant for this patient population, because the side effects of treatment can be so intense."

The group that received standard therapy for up to 48 weeks had a sustained viral response rate of 41 percent, McHutchison said.

The most frequently reported adverse side effect associated with telaprevir was a rash that was manageable in some patients, but caused others to discontinue the treatment, McHutchison said.

"Treating genotype 1 hepatitis C, the most common form of the infection in the United States, can be challenging because the side effects are difficult for many people to endure, the duration of treatment is long, and traditionally less than half of patients are able to be cured of their disease," said Andrew Muir, M.D., a gastroenterologist at Duke and a senior investigator on the study. "Even though telaprevir does produce side effects of its own, its addition to standard therapy was able to improve response rates and shorten the duration of treatment necessary - either one alone would have been an advance, and to be able to achieve both is a significant step in the right direction when it comes to treating hepatitis C."

Peginterferon alfa-2a is an given by injection that is also used to treat HIV and hepatitis B; it works in conjunction with a drug called ribavirin, a nucleoside analogue, to suppress the viral activity of hepatitis C. Side effects can include severe flu-like symptoms, depression, fatigue, insomnia and anemia.

Worldwide, an estimated 180 million people have a chronic infection, and hepatitis C is a leading cause of cirrhosis and liver cancer. It is also the most common condition leading to liver transplantation in the United States.

Source: Duke University Medical Center (news : web)

Explore further: UN says Syria vaccine deaths was an NGO 'mistake'

add to favorites email to friend print save as pdf

Related Stories

New treatment therapy helps inhibit hepatitis C

Jul 31, 2008

Two new studies examine the use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C. The reports appear in the August issue of Hepatology, a journal published by John Wiley & Sons on beh ...

Shorter HCV treatment shows notable success

Jan 02, 2008

[B]It also lowers costs and the risk of serious side effects[/B] Two new randomized controlled trials show that treating Hepatitis C (HCV) with peginterferon and ribavirin for shorter durations can yield success rates sim ...

Researcher Announced Cure for Hepatitis C

May 22, 2007

The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer and the need for liver transplant, a Virginia Commonwealth University researcher ...

Researchers Find New Treatment for Hepatitis C

Apr 11, 2008

Researchers at the Oklahoma University Health Sciences Center have found a new use for an old drug. Their findings appear online in the American Journal of Gastroenterology.

Recommended for you

UN says Syria vaccine deaths was an NGO 'mistake'

1 hour ago

The recent deaths of Syrian children after receiving measles vaccinations was the result of a "mistake" by a non-governmental partner who mixed in a muscle relaxant meant for anesthesia, a spokesman for the U.N. secretary-general ...

First US child dies from enterovirus D68

1 hour ago

A child in the northeastern US state of Rhode Island has become the first to die from an ongoing outbreak of a respiratory virus, enterovirus D68, health officials said Wednesday.

US Ebola patient had contact with kids: governor

1 hour ago

A man who was diagnosed with Ebola in virus in Texas came in contact with young children, and experts are monitoring them for any signs of disease, governor Rick Perry said Wednesday.

UN worker dies of suspected Ebola in Liberia

2 hours ago

The United Nations mission in Liberia announced on Wednesday the first suspected victim among its employees of the deadly Ebola epidemic ravaging the impoverished west African nation.

AAO-HNSF clinical practice guideline: Tinnitus

2 hours ago

The American Academy of Otolaryngology—Head and Neck Surgery Foundation has released the first ever mutli-disciplinary, evidence-based clinical practice guideline to improve the diagnosis and management of tinnitus, the ...

User comments : 0